CGTX
Cognition Therapeutics, Inc.
NASDAQ · USHealthcareBiotechnology
$0.95-1.27%
Price as of Jul 20, 2026
CGTX financials
Cognition Therapeutics, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $235.0K |
| Gross profit | $0.00 | $0.00 | $0.00 | -$235.0K |
| Operating expenses | $47.8M | $54.0M | $50.7M | $43.3M |
| Operating income | -$47.8M | -$54.0M | -$50.7M | -$43.6M |
| Net income | -$23.5M | -$34.0M | -$25.8M | $757.0K |
| EBITDA | -$23.2M | -$33.7M | -$25.5M | -$21.1M |
| Basic EPS | $-0.32 | $-0.85 | $-0.86 | $-0.74 |
| Diluted EPS | $-0.32 | $-0.85 | $-0.86 | $-0.74 |
| Balance sheet | ||||
| Cash & equivalents | $36.8M | $25.0M | $29.9M | $41.6M |
| Total assets | $48.4M | $30.2M | $35.2M | $50.4M |
| Total liabilities | $14.1M | $11.5M | $10.7M | $10.2M |
| Stockholders’ equity | $34.3M | $18.8M | $24.5M | $40.2M |
| Total debt | $638.0K | $814.0K | $1.2M | $1.5M |
| Net debt | -$36.2M | -$24.2M | -$28.7M | -$40.1M |
| Cash flow | ||||
| Operating cash flow | -$24.6M | -$28.5M | -$16.0M | -$18.5M |
| Capital expenditure | $0.00 | -$4.0K | -$147.0K | -$171.0K |
| Free cash flow | -$24.6M | -$28.5M | -$16.2M | -$18.7M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |